Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (June 2017)
25 slides from Inspiremd's investor presentation, Jun 15, 2017
Slide 1: Investor Presentation
inspireMD Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements inspirelMD This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For
Slide 3: About InspireMD
About Inspire MD inspireMD InspireMD is a commercial-stage medical device company with proprietary and innovative embolic prevention systems (EPS)/thrombus management technologies and neurovascular devices that seek to overcome the harmful consequences of conventional stenting. a TECHNOLOGY Propri t
Slide 4: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting inspireMD “Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization,
Slide 5: Consequences Range from Neurological Deficit to Stroke
Consequences Range from Neurological Deficit to Stroke inspire Pre-Procedure Post-Procedure Pre-intervention showing 90% occlusion of the Post-intervention showing successful opening carotid artery and an MRI showing an old white of the occluded carotid artery with conventional matter infarction (ob
Slide 6: MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges
MicroNet™ Prevents Distal Embolization and Other Vascular Disease Challenges Ultrathin PET* mesh provides meaningful clinical benefit versus conventional devices Provides revascularization benefit MicroNet™ acts as a “safety net” by offering greater vessel area coverage to prevent large plaque protr
Slide 7: Conventional Carotid Stents vs CGuard EPS
inspire a opel Conventional Carotid Stents CGuard™ EPS No plaque coverage leading to vulnerable The MicroNet permanently covers thrombus that plaque protrusions or prolapse might be present and the plaque and prevents thrombus or “debris” from passing through the mesh and into the vessel lumen 1/8/2
Slide 8: Large & Growing Addressable Market
Large & Growing Addressable Market inspireMD Embolic Prevention Market CE Mark Focus Products Oppty Area CGuard™ $500M v Carotid MGuard™* : $1.7B Vv Coronary AMI & SVG Planned NGuard™ Va $675M Submission Neurovascular TBD = Planned PVGuard™ aed $1.7B Submission Peripheral TBD * MGuard™ global strate
Slide 9: Positive CGuard Clinical Experience
Positive CGuard™ Clinical Experience inspireMD CARENET Clinical Trial (2014) PARADIGM 101 Clinical Trial (2015 and 2016) 30 Patient Safety and Efficacy clinical trial Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%") 50% fewer new ischemic lesions with lesion
Slide 10: Additional Independent Clinical Data Supports Use of CGuard
Additional Independent Clinical Data Supports ——™s Use of CGuard™ inspireMD Independent study conducted in 30 patients with internal carotid artery disease — ‘Cnical Results and Mechanical Properties ‘the Carodd CGUARD Double- Layered Embolle Prevention Stent Ze Clinical results (2016) - * 100% succ
Slide 11: Additional Independent Clinical Data Presented at LINC 17
Additional Independent Clinical Data Presented at —~ LINC 2017 Further Supports Use of CGuard™ inspireMD SPECIAL ARTICLES, The lron-Guard Registry owoowscsa mas + Physician initiated a - ; - zi 7 Physician-initiated prospective Italian Registry * 12 large Italian medical centers of carotid stenting
Slide 12: Growing KOL Support Across Europe
Growing KOL Support Across Europe inspire Leipzig Interventional Course (LINC) January 2017 European Association of Percutaneous Cardiovascular Interventions (EuroPCR) May 2017 PD Dr. Andrej Schmidt and Dr. Sven Bréunlich Department of Angiology, University Hospital Leipzig, Division of Intervention
Slide 13: Peripheral Interventions: EuroPCR 2017 Highlights
Peripheral Interventions: EuroPCR 2017 ~~ Xe Highlights inspireMD ; PCR IGHTS SHLIGHTS ! J o. Piotr MUSIALEK , Poland + “We know that with the prior generation of [carotid] stents a lot of the [distal embolization] events happen after the procedure” (Prof. Musialek) + “Here [with mesh covered stents
Slide 14: Sales & Marketing Strategy
Sales & Marketing Strategy inspireMD Proven success with regionally strong local distributors; YOY (2015-2016) sales growth 67% Representative Regional Distributors Colombia 100% Israel 151% Italy 59% Slovenia 95% Chile 233% + Replacing exclusive European CGuard™ distributor with regional distributo
Slide 15: Sales & Marketing Strategy
Sales & Marketing Strategy inspireMD Proven success with regionally strong local distributors; 84% sequential increase in sales of CGuard™ in Q1’17 + Expanding global footprint + Successfully attracting KOLs in each of the respective markets Latest Regional Distributors Former Distributor: Europe Re
Slide 16: Revenue Growth - Q1 '17 vs Q4 '16
Revenue Growth - Q1 ‘17 vs Q4 ‘16 inspireMD Total Sequential Growth of 77% using InspireMD Managed Local Distributor Model m= Penumbra Territories CGuard = Local Distributor CGuard m= MGuard 16
Slide 17: CGuard Product Development
CGuard™ Product Development inspireMD * USFDA + Pre-IDE FDAsubmission for CGuard™ February 2017 + Formal FDA meeting held April 2017 FID Y, \ + Planned IDE submission in 2018 * Next generation CGuard™ - 5 French CGuard™ + Minimally invasive devices trending smaller for broader and easier usage + Low
Slide 18: Broad Platform Technology
Broad Platform Technology *Pianing & Development Phase RGuard™ Renal* NGuard™ Neurovascular*, MGuard™ Coronary EPS CGuard™ Carotid EPS MicroNet™ Platform Technology PVGuard™ Peripheral* MGuard™ Drug Eluting* inspireMD 18
Slide 19: Near Term Growth Strategy
Near Term Growth Strategy inspireMD CGuard™ CGuard™ Approved Markets + Engaging distribution partners in countries with current/near-term Argentina Ireland regulatory approval Austria Israel + Seeking additional regulatory approvals in countries that accept CE Mark [E/E fs Italy + Plan to file US FD
Slide 20: Recent/Upcoming Anticipated Milestones
Recent/Upcoming Anticipated Milestones inspireMD v v CGuard: 2018 US. IDE submission Guard launch in Russia: Hi 2017 distribution in AsialPacific 22017 5 French CGuard submission 2018 CGuard approval and launch in India and Mexico: H2 2017 EU market expansion: Germany, Italy, Spain, etc. v v Continu
Slide 21: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD + Proprietary platform technology supported by a robust intellectual property portfolio * Continue to strengthen and broaden patent protection globally to enable future pipeline products PATENT RIGHTS ISSUED ALLOWED PENDING Rest of World 18 2 19 24
Slide 22: Leadership
Leadership Significant track records of success James Barry President and CEO inspireMD sBeson, GBD Craig Shore CFO. Agustin Gago cco ep & i ics GSE Delcath. ® angiodynamics — oir an Chairman Doss A Isaac Blech Vice Chairman yee ~—~e medgenics speinse® Michael Berman Director gBostone GF wreeres™ LU
Slide 23: Investment Highlights
Investment Highlights inspireMD * Multi-billion dollar opportunity for MicroNet™ products for multiple vascular markets + Current stents do not adequately address the risk of post-procedural embolization * Consistent positive clinical trial results positioning CGuard™ as a potential standard-of-care
Slide 24: Financial Snapshot
Financial Snapshot inspireMD NYSE MKT: NSPR Stock Price (6/13/17): Average 3 Month Volume (6/13/17): Shares Outstanding (6/13/17): Shares Outstanding Including full conversion of preferred shares (6/13/17): 170M Market Capitalization including full conversion $95M of preferred shares (6/13/17): Tota
Slide 25: InspireMD Contact
inspireMD James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com